Directory Image
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.

Age-Related Macular Degeneration Therapeutics Pipeline Analysis-Clinical Trials, Results, Patent

Author: Carlos Slim
by Carlos Slim
Posted: Nov 16, 2017
macular degeneration

According to a new research report "Age-related macular degeneration Therapeutic Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments" published by P&S Market Research, Age-related macular degeneration Therapeutic pipeline currently exhibits a pipeline with 55 drug candidates.

Age-related macular degeneration is a disorder that causes loss of vision in a person due to macula damage; macula is that part of an eye, which helps a person to see, it is made up of millions of light-sensing cells which provide sharp and central vision. Age-related macular degeneration progresses slowly in an individual and can eventually lead to blindness. The most common symptom of Age-related macular degeneration is blurry vision. Age-related macular degeneration is common in people who are above the age of 50 years and is of two types namely, Dry Age-related macular degeneration and Wet Age-related macular degeneration. Dry Age-related macular degeneration is the most common form and almost eight out of ten Age-related macular degeneration patients suffer from this type of macular degeneration. Wet Age-related macular degeneration is less common, but is a more serious condition as compared to Dry Age-related macular degeneration. Various companies are developing drugs with promising targets for the treatment of the disease. Targeted therapy is more efficient in achieving good results. The potential targets are expected to possibly stop or slow down the progress of the disease with better efficacy and less side effects. The continuous efforts by various companies to find better and new treatment strategies with potential targets such as mitogen-activated protein kinase, complement factor D, retinal pigment epithelium cell, signal transducer and activator of transcription 3 (STAT3), also prove to be effective in treating Age-related macular degeneration.

The Age-related Macular Degeneration pipeline analysis report covers approximately 55 drug candidates in the pipeline in different stages of development.

Download Sample : https://www.psmarketresearch.com/market-analysis/age-related-macular-degeneration-therapeutics-pipeline-analysis/report-sample

As per the findings of the research, most of the drug candidates of Age-related macular degeneration pipeline are being developed to be administered by intra-vitreal route.

Make Enquiry Before Purchase: https://www.psmarketresearch.com/send-enquiry?enquiry-url=age-related-macular-degeneration-market

Many technologies are being developed that can bring the innovative treatment which can control the progression of Age-related macular degeneration. Some of these technologies include but are not limited to, HINGESCREEN technology platform, and CrossMab technology platform.

There are different novel molecule types that are present in the therapeutic pipeline of Age-related macular degeneration. Opregen is being developed by Cell Cure Neurosciences. Opregen is a stem cells molecule type useful in the treatment of Age-related macular degeneration.

Some of the key players developing drugs for Age-related macular degeneration include Formycon, AG, Allergan Plc, Hoffmann-La Roche, and others.

Contact:

Mr. Kundan Kumar

Manager – Client Partner

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

About the Author

Contact: Mr. Kundan Kumar Manager – Client Partner 347, 5th Ave. #1402 New York City, NY - 10016 Toll-free: +18887787886 (Usa/Canada) Email: enquiry@psmarketresearch.com Web: https://www.psmarketresearch.com

Rate this Article
Leave a Comment
Author Thumbnail
Please or Join to add a comment.
Author: Carlos Slim

Carlos Slim

Italy

Member since: Oct 24, 2017
Published articles: 4

Related Articles